Boston Scientific (NYSE:BSX – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 2.450-2.470 for the period, compared to the consensus EPS estimate of 2.410. The company issued revenue guidance of $16.6 billion-$16.6 billion, compared to the consensus revenue estimate of $16.3 billion. Boston Scientific also updated its Q4 guidance to $0.64-$0.66 EPS.
Boston Scientific Stock Down 1.8 %
Boston Scientific stock traded down $1.59 during midday trading on Thursday, reaching $85.86. The company’s stock had a trading volume of 4,002,365 shares, compared to its average volume of 6,011,844. Boston Scientific has a 52-week low of $49.15 and a 52-week high of $88.79. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The stock has a market capitalization of $125.96 billion, a P/E ratio of 72.02, a PEG ratio of 2.87 and a beta of 0.80. The stock’s 50-day simple moving average is $83.19 and its 200-day simple moving average is $77.57.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the business posted $0.50 EPS. Boston Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, sell-side analysts expect that Boston Scientific will post 2.4 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Research Report on Boston Scientific
Insider Activity at Boston Scientific
In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares in the company, valued at approximately $2,978,734.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the transaction, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 316,253 shares of company stock valued at $26,714,298. 0.50% of the stock is owned by corporate insiders.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
- Five stocks we like better than Boston Scientific
- Breakout Stocks: What They Are and How to Identify Them
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Healthcare Dividend Stocks to Buy
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.